However, there was no statistically significant difference in the effects of SGLT2 inhibitors on reducing the composite of CV mortality or HHF between HFpEF patients with and without the following comorbidities: age, diabetes, obesity (BMI ≥ 30 kg/ m2), impaired renal function (eGFR <60 ml/min/1.73 m2), and history of atrial fibrillation (35). This evidence concerns the gene SLC5A2 and atrial fibrillation.